France Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

  • Published : Aug 2022
  • Report Code : KSI061613352
  • Pages : 75

The France flu diagnostic and treatment market is projected to grow at a CAGR of 14.29% throughout the forecast period to reach US$4,495.605 million in 2027, from US$1,764.622 million in 2020.

The flu diagnostics and treatment market in France is poised to grow on account of the well-established healthcare sector in the country. Healthcare in France is highly supported by government funding as the growing focus of the government on the reduction of out-of-pocket expenditure of the public is of growing concern. Furthermore, Santé Publique the French health ministry stated, that the burden of influenza mortality in nursing homes is high. Moreover, the high intensity of the seasonal outbreaks of flu throughout the country is also one of the key factors that are anticipated to propel the market’s growth opportunities throughout the forecast period and beyond. The increase in the number of hospitalizations and a notable surge in the number of emergency visits due to influenza-like illnesses are the factors that are expected to collectively bolster the flu diagnostic and treatment market growth in coming years.

The French flu diagnostic and treatment market is expected to grow due to frequent flu outbreaks, state-of-the-art healthcare, government support, and quality healthcare for everyone among others.

Santé Publique France is the French Health Agency that keeps a surveillance check on the flu in the country and warns the government about the outbreaks of flu in the country. Furthermore, the agency stated that the intensity of the flu outbreak in the country this year will be significant, which is expected to benefit the market growth of flu diagnostics and treatments in France. The state-of-the-art healthcare sector of the country is also one of the prime factors that are anticipated to supplement the market growth. More than 75% of the expenditure is government-funded to give access to quality healthcare to everyone, especially to the people who do not have any good insurance policies, which is significantly driving the adoption of advanced healthcare treatments and services by people throughout the country. All these factors are projected to collectively amplify the market’s growth during the next five years and beyond.

Product offerings

  • F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
  • Abbott’s introduced ID NOWTM Influenza A & B 2 assay that provides molecular flu results in 13 minutes or less, which is significantly faster than other molecular methods and more accurate than traditional rapid tests. The ability to make efficient treatment decisions is made possible by rapid diagnostic procedures with increased sensitivity.
  • Fujirebio markets the COVID-19 & Influenza A/B detection kit in France. It is a single-use test kit used for the qualitative detection of HA gene from influenza A and B viral antigens and ORFla gene from COVID-19. The kit is compatible with instruments like Applied BiosystemsTM 7500 fast Real-time PCR system, Applied BiiosystemsTM 7500 Real-time PCR system, and QuantStudioTM 5 Real-time PCR system.

COVID-19 Insights

Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020. During the COVID-19 period, as per the French surveillance report, the rate of influenza has decreased significantly in different parts of France. As per the National for Biotechnology Information, several French regions where coronavirus disease has been reported showed a renewed surge in influenza in the general practice-based Sentinelles network. The incident rate per 100000 inhabitants was reported at 599 cases per week, in 2019 (before the pandemic). In 2020 and 2021, the incident rate recorded per 100000 inhabitants was between 15-67, and 45-28 cases throughout the year per week respectively.

Segmentation

  • By Type of Flu
    • Type A
    • Type B
  • By Offering
    • Diagnostics
      • Rapid Influenza Diagnostic Test
      • Rapid Molecular Assay
      • Others
    • Therapeutics
  • By Age Group
    • 0-14 Years
    • 15-64 Years
    • >=65 Years
  • By End-User
    • Hospital Laboratory
    • Outpatient Clinic
    • Reference Laboratory

1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. France Flu Diagnostic and Treatment Market Analysis, By Type of Flu
5.1. Introduction
5.2. Type A
5.3. Type B

6. France Flu Diagnostic and Treatment Market Analysis, By Offering
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics

7. France Flu Diagnostic and Treatment Market Analysis, By Age Group
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years

8. France Flu Diagnostic and Treatment Market Analysis, By End-User 
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory

9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles
10.1. Abbott
10.2. F. Hoffmann-La Roche Ltd
10.3. Quidel Corporation
10.4. Thermo Fisher Scientific Inc.
10.5. H.U. Group Holdings, Inc
10.6. OPTI Medical Systems, Inc.

Abbott

F. Hoffmann-La Roche Ltd

Quidel Corporation

Thermo Fisher Scientific Inc.

H.U. Group Holdings, Inc

OPTI Medical Systems, Inc.